NHS widens access to weight-loss jab as GP prescribing threshold lowered

More people in England will become eligible for the weight-loss medicine tirzepatide on the NHS from 23 June, as the threshold for prescribing in primary care is lowered. The change is the latest step in a deliberately phased rollout of the drug, sold under the brand name Mounjaro, which is being introduced gradually to manage demand and ensure patients receive proper support alongside their prescription.

Under the expansion, NHS England's primary-care eligibility broadens to include patients with a body mass index of 35 to 39.9, with lower figures applied for some ethnic groups, who also have four or more qualifying weight-related health conditions. Previously, primary-care prescribing was restricted to people with a higher BMI, so the move opens the door to a larger group living with obesity and its complications.

This article is general information about an NHS prescribing policy and is not medical advice. Whether any individual is suitable for tirzepatide is a decision for a clinician based on a full assessment.

What is changing

Tirzepatide belongs to a class of medicines that mimic gut hormones to reduce appetite and help regulate blood sugar. It has been the subject of intense public interest, and the NHS has been clear from the outset that access would be rolled out in stages rather than all at once. The June change adjusts who can be considered within general practice, while keeping clinical assessment and monitoring central to the process.

• From 23 June, primary-care eligibility expands to BMI 35 to 39.9, with adjusted figures for some ethnic groups
• Patients must also have four or more qualifying weight-related conditions
• Prescribing of tirzepatide is included within the GP contract that took effect on 1 April 2026
• GP practices are not mandated to prescribe, so availability varies locally
• Access also depends on local Integrated Care Board arrangements and capacity

Importantly, GP practices are not obliged to prescribe the drug, and arrangements differ between areas. Meeting the eligibility criteria does not guarantee a prescription, because access depends on local service availability, capacity and a clinician's judgement that the medicine is appropriate.

Why the rollout is phased

The staged approach reflects both the scale of potential demand and the need for what the NHS calls wraparound care. The medicines are not a standalone fix; they are intended to be used alongside support on diet, physical activity and behaviour change, with monitoring for side effects. Introducing the drug gradually is designed to avoid overwhelming services and to ensure patients are followed up properly rather than simply handed a prescription.

That caution also acknowledges the pressures on general practice. Adding a new and popular treatment to GPs' workload without adequate support risks straining a system already managing high demand, which is part of why prescribing has been folded into contractual arrangements and phased over time.

“These medicines can be genuinely transformative for the right patients, but they work best as part of a wider package of support, not as a quick fix handed out in isolation.”

— a clinician in primary care

What it means for patients

For people living with obesity and related conditions such as type 2 diabetes, high blood pressure or cardiovascular disease, the lower threshold means more may now be able to discuss the option with their GP. But the variation between practices and areas means experiences will differ, and some patients may find their local service is not yet offering the medicine despite their eligibility on paper.

Clinicians stress that tirzepatide is not suitable for everyone, can have side effects, and requires ongoing review. The expansion changes who can be considered, not the careful, individualised nature of the decision itself.

Background

Obesity is one of the most significant public-health challenges facing the UK, linked to a wide range of serious conditions and to substantial pressure on the NHS. The arrival of highly effective weight-loss medicines has been hailed as a potential turning point, but also raised difficult questions about cost, capacity and equity of access. The phased NHS rollout, with prescribing built into the GP contract from April, is the system's attempt to balance promise against practicality.

What happens next

Further phases of the rollout are expected to widen eligibility over time, subject to capacity and clinical guidance. Patients who think they might qualify are advised to wait for, or ask about, local arrangements rather than assuming automatic access. The June change marks another incremental step in a long-term effort to make these medicines available to those who could benefit, without destabilising the services that deliver them.